Phase II Trial of Combination Intraperitoneal Cisplatin and 5-Fluorouracil in Previously Treated Patients with Advanced Ovarian Cancer: Long-Term Follow-up

2000 ◽  
Vol 77 (3) ◽  
pp. 433-438 ◽  
Author(s):  
Robert J. Morgan ◽  
Patricia Braly ◽  
Lucille Leong ◽  
Stephen Shibata ◽  
Kim Margolin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Ovarian Cancer ◽  
Long Term Follow Up ◽  
Previously Treated Patients ◽  
Previously Treated

Phase II Trial of Intraperitoneal Cisplatin with Intravenous Doxorubicin and Cyclophosphamide in Previously Untreated Patients with Advanced Ovarian Cancer—Long-Term Follow-Up

1999 ◽  
Vol 75 (3) ◽  
pp. 419-426 ◽  
Author(s):  
Robert J. Morgan ◽  
Patricia Braly ◽  
Gary Cecchi ◽  
Lucille Leong ◽  
Stephen Shibata ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Advanced Ovarian Cancer ◽  
Long Term Follow Up

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

2003 ◽  
Vol 13 (Suppl 2) ◽  
pp. 144-148 ◽  
Author(s):  
M. J. Piccart ◽  
K. Bertelsen ◽  
G. Stuart ◽  
J. Cassidy ◽  
C. Mangioni ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Randomized Clinical Trials ◽  
Advanced Ovarian Cancer ◽  
Progression Free Survival ◽  
Clinical Response Rate ◽  
Free Survival ◽  
Long Term Follow Up ◽  
Clinically Significant

Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document